Prohost Letter #394 Part 2
PART 2 - Part 1 of the Prohost letter issue #394 posted on March 31,2016 ended with the review of Ariad Pharmaceuticals (ARIA), one of the biotech firms that have at least one marketed product that we believe have the chance to boost their revenues in the near-future. In this part 2 of the same Prohost Letter, we add other firms that were also picked as shown in the Prohost portfolio table at the end of this second part of the Prohost letter. The added firms are Seattle Genetics (SGEN) and Immunogen . . .
This content is for paid subscribers.
Prohost Letters April 4, 2016